---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/39293187.md"
description: "1. Patents in multiple countries have expired.2. Head-to-head trial failed.3. GLP-1 drugs face massive price cuts in US Medicare.What other horror stories are there? Market makers, post a few more.$Novo Nordisk AS(NVO.US)"
datetime: "2026-03-16T18:34:49.000Z"
locales:
  - [en](https://longbridge.com/en/topics/39293187.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/39293187.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/39293187.md)
author: "[满仓等暴涨](https://longbridge.com/en/profiles/19144251.md)"
---

# 1. Patents in multiple countries have expired.2. H…


### Related Stocks

- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [GLP.US](https://longbridge.com/en/quote/GLP.US.md)
- [UPS.US](https://longbridge.com/en/quote/UPS.US.md)
- [GLP-B.US](https://longbridge.com/en/quote/GLP-B.US.md)

## Comments (2)

- **交易员7.27 · 2026-03-17T01:54:34.000Z**: The pharmaceutical sector lacks potential.
- **龙场悟道忘忧草 · 2026-03-16T21:51:55.000Z**: Why on earth did this thing get cut in half so much, dropping almost 70%?